Meeting
2013 ASCO Annual Meeting
Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Authors
Wenhua Liang
Cancer Center, Sun Yat-Sen University, Guangzhou, China
Wenhua Liang , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8089)
DOI
10.1200/jco.2013.31.15_suppl.8089
Abstract #
8089
Poster Bd #
38E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Adding VEGFR-TKIs to chemotherapy and/or hormonal therapy in advanced breast cancer patients: Results of a meta-analysis.
First Author: Yucai Wang
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan
Poster
2022 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.
First Author: Bradley Alexander McGregor
Poster
2018 Genitourinary Cancers Symposium
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of high-risk clear cell renal carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida